168 related articles for article (PubMed ID: 36607583)
1. How ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini S; Tramontano D; Minicocci I; Di Costanzo A; Tambaro F; D'Erasmo L; Arca M
Curr Atheroscler Rep; 2023 Jan; 25(1):19-29. PubMed ID: 36607583
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
Khoury E; Croteau L; Lauzière A; Gaudet D
Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
[TBL] [Abstract][Full Text] [Related]
3. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
4. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
Mohamed F; Botha TC; Raal FJ
Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
7. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
Pirillo A; Catapano AL
Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
9. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
Gao Y; Zhang B; Yang J
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
[TBL] [Abstract][Full Text] [Related]
10. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism.
Burks KH; Xie Y; Gildea M; Jung IH; Mukherjee S; Lee P; Pudupakkam U; Wagoner R; Patel V; Santana K; Alisio A; Goldberg IJ; Finck BN; Fisher EA; Davidson NO; Stitziel NO
J Lipid Res; 2024 Feb; 65(2):100500. PubMed ID: 38219820
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
[TBL] [Abstract][Full Text] [Related]
14. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
Surma S; Romańczyk M; Filipiak KJ
Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
[TBL] [Abstract][Full Text] [Related]
16. Evinacumab for treatment of familial hypercholesterolemia.
Warden BA; Duell PB
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):739-751. PubMed ID: 34253139
[No Abstract] [Full Text] [Related]
17. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
18. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment.
Lang W; Frishman WH
Cardiol Rev; 2019; 27(4):211-217. PubMed ID: 31008773
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia.
Di Costanzo A; Di Leo E; Noto D; Cefalù AB; Minicocci I; Polito L; D'Erasmo L; Cantisani V; Spina R; Tarugi P; Averna M; Arca M
J Clin Lipidol; 2017; 11(5):1234-1242. PubMed ID: 28733173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
